⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Deep Intelligent Pharma (DIP) and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Deep Intelligent Pharma (DIP) is an AI-native pharmaceutical R&D platform that leverages multi-agent intelligence to automate and optimize the drug development lifecycle. The company provides solutions for drug discovery, medical writing, regulatory support, and clinical trial management, aiming to reduce costs and compress development timelines for global pharmaceutical and biotech companies.
The company is recognized for its "Digital Rehearsal" technology, which simulates clinical trials before they begin, and its multilingual AI medical writing capabilities. DIP serves major global pharmaceutical clients, including Roche, GSK, Bayer, and Bristol Myers Squibb, by integrating AI with domain expertise to enhance R&D efficiency.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:AI-powered Drug Discovery & Clinical Trial Automation
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series E
Total Raised:$125M
Investors:CDH Investments, CDH Baifu, HSG
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Technology Platform)
Modalities:AI-driven R&D
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Roche, GSK, Bayer, Bristol Myers Squibb (BMS), Immunorock
COMPETITION
Position:Emerging
Competitors:Recursion Pharmaceuticals, Healx, XtalPi, Insilico Medicine, Atomwise
LEADERSHIP
Key Executives:
Li Xing - Founder
Scientific Founders:Li Xing
LINKS
Website:dip-ai.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Deep Intelligent Pharma (DIP). The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.